Alnylam completes enrollment in illuminate-c phase 3 study of lumasiran, an rnai therapeutic, for the treatment of advanced primary hyperoxaluria type 1

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that it has achieved full patient enrollment in its illuminate-c phase 3 study of lumasiran, an rnai therapeutic targeting hydroxyacid oxidase 1 (hao1) – the gene encoding glycolate oxidase (go) – for the treatment of adults and children with advanced primary hyperoxaluria type 1 (ph1). enrollment was completed with 21 ph1 patients across 13 sites in 10 countri
ALNY Ratings Summary
ALNY Quant Ranking